CelLBxHealth shares rise 8% on Royal Marsden lung cancer collaboration

CelLBxHealth PLC (AIM:CLBX, FRA:DWV) shares rose 8% to 0.99p after the AIM-listed circulating tumour cell specialist announced a research collaboration with The Royal Marsden NHS Foundation Trust to study a novel blood-based testing approach in advanced lung cancer patients. The two organisations will jointly conduct a clinical study in 200 patients with advanced non-small cell lung cancer (NSCLC), the most common form of the disease.